Supplementary Table 5 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma

Supplementary Table 5 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma

<p>Supplementary Table 5 shows the results of NSD2-MASPEC in KMS11 cells.</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Yunlu Jia (2012017) (author)
Autres auteurs:	Jianbiao Zhou (14935538) (author), Tze King Tan (15203447) (author), Tae-Hoon Chung (4343) (author), Yongxia Chen (424187) (author), Jing-Yuan Chooi (4238347) (author), Takaomi Sanda (15203450) (author), Melissa J. Fullwood (14195681) (author), Sinan Xiong (6175022) (author), Sabrina H.M. Toh (15203453) (author), Kalpnaa Balan (15203456) (author), Regina W.J. Wong (15203459) (author), Julia S.L. Lim (14935541) (author), Enfan Zhang (9965455) (author), Zhen Cai (576458) (author), Peng Shen (688111) (author), Wee Joo Chng (14959944) (author)
Publié:	2025
Sujets:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Mechanisms of transcription Hematological Cancers Myelomas Oncogenes & Tumor Suppressors Oncogenes
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Supplementary Table 1 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
par: Yunlu Jia (2012017)
Publié: (2025)

Supplementary Table 2 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
par: Yunlu Jia (2012017)
Publié: (2025)

Supplementary Table 3 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
par: Yunlu Jia (2012017)
Publié: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
par: Smruthy Sivakumar (15053536)
Publié: (2025)

Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
par: Lijun Yao (15292963)
Publié: (2025)

Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
par: Lijun Yao (15292963)
Publié: (2025)

Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
par: Lijun Yao (15292963)
Publié: (2025)

Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
par: Lijun Yao (15292963)
Publié: (2025)

Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
par: Lijun Yao (15292963)
Publié: (2025)

Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
par: Lijun Yao (15292963)
Publié: (2025)

Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
par: Keiji Kurata (15055090)
Publié: (2025)

Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
par: Keiji Kurata (15055090)
Publié: (2025)

Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
par: Keiji Kurata (15055090)
Publié: (2025)

Supplementary Spreadsheet S1 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S10 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S11 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S12 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S4 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S5 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S6 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S7 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S8 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Supplementary Spreadsheet S9 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
par: Eileen M. Boyle (15015425)
Publié: (2025)

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
par: Kazuhito Suzuki (22688384)
Publié: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
par: Feng Wang (44414)
Publié: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
par: Feng Wang (44414)
Publié: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
par: Feng Wang (44414)
Publié: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
par: Feng Wang (44414)
Publié: (2025)

Supplementary Movie 1 from The Macrophage-Associated LncRNA <i>MALR</i> Facilitates ILF3 Liquid–Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer
par: Jia Liu (15386858)
Publié: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
par: Craig M. Goodwin (14955973)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_dq3a7p769kblogqpbhf28ksu2d